Erectile Dysfunction Clinical Trial
— ERECTIONOfficial title:
The Impact of a Plant-Based Diet Versus an Animal-Based Diet on Erectile Function in Healthy Men With Normal Erectile Function: The ERECTION Study
The goal of this study is to determine whether erectile function is impacted by dietary patterns in healthy men with normal erectile function.
| Status | Recruiting |
| Enrollment | 46 |
| Est. completion date | December 2024 |
| Est. primary completion date | December 2024 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Male |
| Age group | 18 Years to 35 Years |
| Eligibility | Inclusion Criteria: - Subject provides written informed consent and HIPAA authorization in English before any study procedures are conducted. - Subject is taking no medical therapy other than: prn MDIs, medication(s) for anxiety, depression, and/or ADHD (these medications include, but are not limited to, SSRIs, SNRIs, Stimulants), no change in supplements if applicable. The anxiety, depression, and/or ADHD will have been controlled (per report of subject) for the last 6 months. - IIEF score greater or equal to 22 - Subject will have had penile-sexual intercourse (either vaginal or anal penetration) within 12 weeks of enrollment. - Male aged 18-35 years old - Lives within commuting distance of Montefiore Health System - Subject's significant other (if applicable) agrees to support the subject during the study - Subject agrees to photograph and share all items consumed/drunk during the dietary intervention - Subject agrees to avoid all illicit drugs, NSAIDS, and alcohol for at least two days prior to Rigiscan™ recording and on the days and nights of Rigiscan™ recording - Subject agrees to refrain from sexual activity for at least 24 hours prior to Rigiscan™ placement and to have no sexual activity on the days and nights of Rigiscan™ recording. - Subject agrees to not view, read, or otherwise consume erotic or pornographic material for 24 hours prior to both the days and nights of Rigiscan™ recording and on the days and nights of Rigiscan™ recording. - Subject agrees to not have an orgasm for 24 hours prior to both the days and nights of RigiscanTM recording and on the days and nights of Rigiscan™ recording. - Subject agrees to come to Montefiore to undergo Rigiscan™ training - Subject agrees to only consume/drink permitted food/beverages. - Subject agrees to attend all in person visits at Montefiore, to begin fasting at 11pm the night before each visit, and to undergo all blood draws/salivary/other testing. - Subject agrees to not use mouthwash or mouth rinses or intentionally spit for the entire duration of the study. Subjects will be asked to refrain from using mouthwash for at least 2 days prior to enrollment. Subject agrees to not brush his teeth in the morning of the day of each study visit. Tooth brushing is otherwise permissible. - BMI <30, BMI >=18.5, weight >110 lbs. - Subject agrees to comply with the study procedures and visits. - Subject exercises for at least 15 minutes at least two times per week - If exercise is done, subjects will exercise for the same amount of time and at a similar intensity each day of Rigiscan™ testing. Otherwise, no exercise will be performed on Rigiscan™ days. - If enrolled, subjects agree to not modify their dietary habits throughout the duration of the study other than during the two evenings and two full days when food is provided. Exclusion Criteria: - Relevant dietary allergy - Vegetarian or Vegan dietary pattern - History of an eating disorder and/or food addiction - Hypertension and or history of hypertension with or without medical treatment. Systolic blood pressure > 150mmHg and/or diastolic blood pressure >100mmHg on Visit one. Heart rate >99 on Visit one. Systolic blood pressure < 85mmHg and/or diastolic blood pressure < 50mmHg on Visit one. Heart rate < 35 on Visit one. - BMI >=30, BMI <18.5, or weight <= 110lbs - Known chronic medical disease other than non-inflammatory musculoskeletal disease, asthma, anxiety, depression, and/or ADHD. Subjects who have had changes in the dosage or type of their medication(s) for anxiety, depression, and/or ADHD within 3 months of enrollment. Subjects who have scheduled or planned medication and/or medication dose changes during the study period. These medication changes include the initiation of a new medication, discontinuation of a medication, modification of medication dose, and/or the route of administration of a medication. Subjects who are taking benzodiazepines and/or beta blockers - History of kidney disease or hyperkalemia - Subject has received an investigational drug within 30 days prior to signing consent - Erectile dysfunction - Has any condition (e.g., psychiatric illness) or situation that, in the investigator's opinion, may confound the study results, or may interfere significantly with the patient's ability to adhere with study procedures - Currently undergoing treatment for Peyronie's Disease - Abnormal Testosterone or Thyroid Stimulating Hormone level - Treated hypogonadism or hypothyroidism - Planned travel during the study - The subject is trans-gender - History of substance abuse in the last 12 months - Illicit drug use, smoking, or vaping within 4 weeks - Upper respiratory illness within two weeks on screening - If profession requires being on call, no overnight or on call duties during the study - Subject reports any communicable skin or venereal disease - Subject reports rash or lesion on the penis or surrounding area. - STOP-Bang score > 2 - Having the diagnosis of Restless Leg Syndrome. - Having insomnia as defined by: Subject with insomnia would have difficulty initiating or maintaining sleep (30 minutes or more at sleep initiation or 30 minutes or more to fall back asleep if wakes during the night). The above occurs at least 3 times per week for at least 1 month. Furthermore, there must be adequate opportunity for sleep and there must be associated morbidity (feels tired during the day). Definition based on: The International Classification of Sleep Disorders - Third Edition (ICSD-3), 2014. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Montefiore Medical Center, Department of Medicine, Division of Cardiology | Bronx | New York |
| Lead Sponsor | Collaborator |
|---|---|
| Montefiore Medical Center | The Greenbaum Foundation, The Purjes Foundation |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Heart rate | Comparing heart rate by dietary pattern at both time points (after overnight sleep after consuming the 1 meal and after overnight sleep after consuming the 4 meals) and compared to its respective baseline in beats/minute. Definition: In regard to the following anthropometric, vital sign, and laboratory data (blood, urine, and saliva) pre-specified outcomes included in this pre-specified outcomes section, at "both time points" is defined as in the sentence above and "respective baseline" refers to either visit 2 or visit 5, as visit 2 is the baseline for one dietary arm (plant or animal) and visit 5 is the baseline for the other dietary arm (plant or animal). | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Blood Pressure | Comparing blood pressure by dietary pattern at both time points and compared to its respective baseline in mmHg | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Weight | Comparing weight by dietary pattern at both time points and compared to its respective baseline | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Fibrinogen | Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | D-dimer | Comparing it at both time points by dietary pattern and compared to its respective baseline in ng/mL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Total cholesterol | Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | HDL cholesterol | Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | HDL efflux capacity | Comparing it at both time points by dietary pattern and compared to its respective baseline. | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | LDL cholesterol | Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Triglyceride | Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Oxidized LDL cholesterol | Comparing it at both time points by dietary pattern and compared to its respective baseline in U/L | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Free Fatty Acids | Comparing it at both time points by dietary pattern and compared to its respective baseline in micromoles | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Myeloperoxidase | Comparing it at both time points by dietary pattern and compared to its respective baseline in ug/L | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Factor VII | Comparing it at both time points by dietary pattern and compared to its respective baseline in percentage. | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | lysolecithin | Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/mL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Apolipoprotein B | Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Omega 3 index | Comparing it at both time points by dietary pattern and compared to its respective baseline in percentage of erythrocyte fatty acid | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Lipoprotein-associated phospholipase-A2 (Lp PLA2) activity | Comparing it at both time points by dietary pattern and compared to its respective baseline in nmol/min/mL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Lipoprotein (a) | Comparing it at both time points by dietary pattern and compared to its respective baseline in nmol/L | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Homocysteine | Comparing it at both time points by dietary pattern and compared to its respective baseline in umol/L | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | methylmalonic acid (MMA) | Comparing it at both time points by dietary pattern and compared to its respective baseline in umol/L | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Asymmetric Dimethylarginine (ADMA) | Comparing it at both time points by dietary pattern and compared to its respective baseline in umol/L | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | symmetric dimethylarginine (SDMA) | Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Total testosterone | Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Sex Hormone Binding Globulin | Comparing it at both time points by dietary pattern and compared to its respective baseline in nmol/L | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | cystatin C | Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | remnant cholesterol particles | Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | uric acid | Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | interleukin 1 | Comparing it at both time points by dietary pattern and compared to its respective baseline in pg/mL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | interleukin 6 | Comparing it at both time points by dietary pattern and compared to its respective baseline in pg/mL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | hsCRP | Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/L | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Blood Urea Nitrogen (BUN) | Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Carbon Dioxide (CO2) | Comparing it at both time points by dietary pattern and compared to its respective baseline in mmol/L | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | creatinine | Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | glucose | Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | serum chloride | Comparing it at both time points by dietary pattern and compared to its respective baseline in meq/L | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | serum potassium | Comparing it at both time points by dietary pattern and compared to its respective baseline in meq/L | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | serum sodium | Comparing it at both time points by dietary pattern and compared to its respective baseline in meq/L | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | alanine aminotransferase (ALT) | Comparing it at both time points by dietary pattern and compared to its respective baseline in units/L | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | aspartate aminotransferase (AST) | Comparing it at both time points by dietary pattern and compared to its respective baseline in units/L | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | estimated glomerular filtration rate (eGFR) | Comparing it at both time points by dietary pattern and compared to its respective baseline in mL/min/1.73m2 | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | vitamin c | Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | reduced glutathione | Comparing it at both time points by dietary pattern and compared to its respective baseline in umol/L | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | superoxide dismutase | Comparing it at both time points by dietary pattern and compared to its respective baseline in ng/mL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | vitamin e | Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/L | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | selenium | Comparing it at both time points by dietary pattern and compared to its respective baseline in ng/mL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | malondialdehyde | Comparing it at both time points by dietary pattern and compared to its respective baseline in umol/L | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | non coding RNA | Comparing it at both time points by dietary pattern and compared to its respective baseline in copies/mL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | micro RNA | Comparing it at both time points by dietary pattern and compared to its respective baseline in copies/mL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Lnc RNA | Comparing it at both time points by dietary pattern and compared to its respective baseline in copies/mL | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | trimethylamine-N-oxide (TMAO) | Comparing it at both time points by dietary pattern and compared to its respective baseline in umol/L | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | phenylacetylglutamine (PAG) | Comparing it at both time points by dietary pattern and compared to its respective baseline in uM (micrometers) | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Comparing urine albumin-to-creatinine ratio (UACR) | Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/g | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Comparing salivary nitrite level as a correlate of plasma nitric oxide (NO) level | Comparing it at both time points by dietary pattern and compared to its respective baseline in micromoles/L | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Comparing salivary nitrate level in as a correlate of plasma nitric oxide (NO) level | Comparing it at both time points by dietary pattern and compared to its respective baseline in micromoles/L | Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7) | |
| Other | Percent of time =50% erect during overnight sleep after 4 meals. | Total time (in minutes) when penile rigidity is =50% at both the tip and the base of the penis as measured by Rigiscan™ during overnight sleep, divided by the total time (in minutes) of overnight sleep. Overnight sleep is defined as the time in minutes from the onset of the first nocturnal erection to the end of the last nocturnal erection (as measured by Rigiscan™). | During overnight sleep directly after consuming the 4 meals. | |
| Other | Percent of time =50% erect during overnight sleep after 1 meal. | Total time (in minutes) when penile rigidity is =50% at both the tip and the base of the penis as measured by Rigiscan™ during overnight sleep, divided by the total time (in minutes) of overnight sleep. Overnight sleep is defined as the time in minutes from the onset of the first nocturnal erection to the end of the last nocturnal erection (as measured by Rigiscan™). | During overnight sleep directly after consuming the 1 meal. | |
| Other | Erection events per hour during overnight sleep after 1 meal. | Total number of erection events lasting =5 minutes and with =70% rigidity at both the tip and the base of the penis as measured by Rigiscan™ during overnight sleep. Overnight sleep is defined as the time in minutes from the onset of the first nocturnal erection to the end of the last nocturnal erection (as measured by Rigiscan™). This result will be reported as Events/hour. | During overnight sleep directly after consuming the 1 meal. | |
| Other | Tumescence events per hour during overnight sleep after 1 meal. | Total number of tumescence events lasting =5 minutes and when penile circumference increases by =2cm at both the tip and the base of the penis compared to their respective baselines as measured by Rigiscan™ during overnight sleep, divided by the total time (in minutes) of overnight sleep. Overnight sleep is defined as the time in minutes from the onset of the first nocturnal erection to the end of the last nocturnal erection (as measured by Rigiscan™). This result will be reported as Tumescence events/hour. | During overnight sleep directly after consuming the 1 meal. | |
| Other | Percent of time =70% erect during overnight sleep after 4 meals versus after 1 meal by dietary pattern. | This outcome will evaluate whether a difference is present in the percent of time =70% erect during overnight sleep (as defined in outcomes above) directly after consuming the 4 meals versus directly after consuming the 1 meal by dietary pattern, for each dietary pattern. (e.g. is there a greater percentage of time =70% erect on the second night versus the first night when consuming the plant-based diet?). | During overnight sleep directly after consuming the 4 meals versus overnight sleep directly after consuming the 1 meal by dietary pattern, for each dietary pattern. | |
| Other | Percent of time =50% erect during overnight sleep after 4 meals versus after 1 meal by dietary pattern. | This outcome will evaluate whether a difference is present in the percent of time =50% erect during overnight sleep (as defined in outcomes above) directly after consuming the 4 meals versus directly after consuming the 1 meal by dietary pattern, for each dietary pattern. (e.g. is there a greater percentage of time =50% erect on the second night versus the first night when consuming the plant-based diet?). | During overnight sleep directly after consuming the 4 meals versus overnight sleep directly after consuming the 1 meal by dietary pattern, for each dietary pattern. | |
| Other | Tumescence events per hour during overnight sleep after 4 meals versus after 1 meal by dietary pattern. | This outcome will evaluate whether a difference is present in the total number of tumescence events per hour (as defined in outcomes above) directly after consuming the 4 meals versus directly after consuming the 1 meal by dietary pattern, for each dietary pattern. (e.g. is there a greater of tumescence events per hour on the second night versus the first night when consuming the plant-based diet?). | During overnight sleep directly after consuming the 4 meals versus overnight sleep directly after consuming the 1 meal by dietary pattern, for each dietary pattern. | |
| Primary | Percent of time =70% erect during overnight sleep after 4 meals. | Total time (in minutes) when penile rigidity is = 70% at both the tip and the base of the penis as measured by Rigiscan™ during overnight sleep, divided by the total time (in minutes) of overnight sleep. Overnight sleep is defined as the time in minutes from the onset of the first nocturnal erection to the end of the last nocturnal erection (as measured by Rigiscan™). | During overnight sleep directly after consuming the 4 meals. | |
| Secondary | Percent of time =70% erect during overnight sleep after 1 meal. | Total time (in minutes) when penile rigidity is =70% at both the tip and the base of the penis as measured by Rigiscan™ during overnight sleep, divided by the total time (in minutes) of overnight sleep. Overnight sleep is defined as the time in minutes from the onset of the first nocturnal erection to the end of the last nocturnal erection (as measured by Rigiscan™). | During overnight sleep directly after consuming the 1 meal. | |
| Secondary | Erection events per hour during overnight sleep after 4 meals. | Total number of erection events lasting =5 minutes and with =70% rigidity at both the tip and the base of the penis as measured by Rigiscan™ during overnight sleep. Overnight sleep is defined as the time in minutes from the onset of the first nocturnal erection to the end of the last nocturnal erection (as measured by Rigiscan™). This result will be reported as Events/hour. | During overnight sleep directly after consuming the 4 meals. | |
| Secondary | Tumescence events per hour during overnight sleep after 4 meals. | Total number of tumescence events lasting =5 minutes and when penile circumference increases by =2cm at both the tip and the base of the penis compared to their respective baselines as measured by Rigiscan™ during overnight sleep, divided by the total time (in minutes) of overnight sleep. Overnight sleep is defined as the time in minutes from the onset of the first nocturnal erection to the end of the last nocturnal erection (as measured by Rigiscan™). This result will be reported as Tumescence events/hour | During overnight sleep directly after consuming the 4 meals. |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
| Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
| Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
| Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
| Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
| Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
| Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
| Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
| Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
| Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
| Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
| Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
| Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
| Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
| Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
| Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
| Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
| Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 | |
| Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 | |
| Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 |